Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma?

Gi Hong Choi, Dong Hyun Kim, ChangMoo Kang, Kyung Sik Kim, Jin Sub Choi, Woo Jung Lee, Byong Ro Kim

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Whether preoperative transarterial chemoembolization (TACE) has the therapeutic benefits in patients with resectable hepatocellular carcinoma (HCC) remains uncertain. Materials and methods: We retrospectively investigated the influence of preoperative TACE on both disease-free survival and the pattern of recurrence after curative resection. From March 1998 to January 2005, a series of 273 patients who underwent curative resection for HCC were reviewed. Altogether, 120 patients underwent preoperative TACE, and 153 patients did not. We compared disease-free survival and the recurrence patterns between TACE and non-TACE groups, as well as between subgroups, stratified with regard to initial tumor size (≤3 cm, 3-5 cm, >5 cm) and pathologic tumor stage (stage I-II and stage III-IVa). We also compared disease-free survival and the pattern of recurrence among the three groups: complete necrosis, incomplete necrosis, non-TACE groups. Results: The 1-, 3-, and 5-year disease-free survival rates were 76.0%, 57.7%, and 51.3%, respectively, in the TACE group and 70.9%, 53.8%, and 46.8%, respectively, in the non-TACE group. No significant difference was observed in disease-free survival or the pattern of recurrence between the TACE and non-TACE groups. Further analysis of disease-free survival and the pattern of recurrence between subgroups according to initial tumor size and tumor stage showed no significant differences. Complete necrosis of tumor was recognized in only 33 patients of the TACE group (p = 0.001). Among the three complete necrosis, incomplete necrosis, and non-TACE groups, no significant difference was observed in disease-free survival or the pattern of recurrence. Conclusions: Preoperative TACE did not significantly improve the disease-free survival or the pattern of recurrence after curative resection of HCC. Even though this study is a retrospective analysis, preoperative TACE cannot be recommended as a routine procedure before hepatectomy for a resectable HCC.

Original languageEnglish
Pages (from-to)2370-2377
Number of pages8
JournalWorld Journal of Surgery
Volume31
Issue number12
DOIs
Publication statusPublished - 2007 Dec 1

Fingerprint

Disease-Free Survival
Hepatocellular Carcinoma
Recurrence
Necrosis
Neoplasms
Therapeutic Chemoembolization
Hepatectomy
Survival Rate

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Choi, Gi Hong ; Kim, Dong Hyun ; Kang, ChangMoo ; Kim, Kyung Sik ; Choi, Jin Sub ; Lee, Woo Jung ; Kim, Byong Ro. / Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma?. In: World Journal of Surgery. 2007 ; Vol. 31, No. 12. pp. 2370-2377.
@article{cba5420b013548eeb85fe243ee031e1d,
title = "Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma?",
abstract = "Background: Whether preoperative transarterial chemoembolization (TACE) has the therapeutic benefits in patients with resectable hepatocellular carcinoma (HCC) remains uncertain. Materials and methods: We retrospectively investigated the influence of preoperative TACE on both disease-free survival and the pattern of recurrence after curative resection. From March 1998 to January 2005, a series of 273 patients who underwent curative resection for HCC were reviewed. Altogether, 120 patients underwent preoperative TACE, and 153 patients did not. We compared disease-free survival and the recurrence patterns between TACE and non-TACE groups, as well as between subgroups, stratified with regard to initial tumor size (≤3 cm, 3-5 cm, >5 cm) and pathologic tumor stage (stage I-II and stage III-IVa). We also compared disease-free survival and the pattern of recurrence among the three groups: complete necrosis, incomplete necrosis, non-TACE groups. Results: The 1-, 3-, and 5-year disease-free survival rates were 76.0{\%}, 57.7{\%}, and 51.3{\%}, respectively, in the TACE group and 70.9{\%}, 53.8{\%}, and 46.8{\%}, respectively, in the non-TACE group. No significant difference was observed in disease-free survival or the pattern of recurrence between the TACE and non-TACE groups. Further analysis of disease-free survival and the pattern of recurrence between subgroups according to initial tumor size and tumor stage showed no significant differences. Complete necrosis of tumor was recognized in only 33 patients of the TACE group (p = 0.001). Among the three complete necrosis, incomplete necrosis, and non-TACE groups, no significant difference was observed in disease-free survival or the pattern of recurrence. Conclusions: Preoperative TACE did not significantly improve the disease-free survival or the pattern of recurrence after curative resection of HCC. Even though this study is a retrospective analysis, preoperative TACE cannot be recommended as a routine procedure before hepatectomy for a resectable HCC.",
author = "Choi, {Gi Hong} and Kim, {Dong Hyun} and ChangMoo Kang and Kim, {Kyung Sik} and Choi, {Jin Sub} and Lee, {Woo Jung} and Kim, {Byong Ro}",
year = "2007",
month = "12",
day = "1",
doi = "10.1007/s00268-007-9245-6",
language = "English",
volume = "31",
pages = "2370--2377",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "12",

}

Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma? / Choi, Gi Hong; Kim, Dong Hyun; Kang, ChangMoo; Kim, Kyung Sik; Choi, Jin Sub; Lee, Woo Jung; Kim, Byong Ro.

In: World Journal of Surgery, Vol. 31, No. 12, 01.12.2007, p. 2370-2377.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma?

AU - Choi, Gi Hong

AU - Kim, Dong Hyun

AU - Kang, ChangMoo

AU - Kim, Kyung Sik

AU - Choi, Jin Sub

AU - Lee, Woo Jung

AU - Kim, Byong Ro

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Background: Whether preoperative transarterial chemoembolization (TACE) has the therapeutic benefits in patients with resectable hepatocellular carcinoma (HCC) remains uncertain. Materials and methods: We retrospectively investigated the influence of preoperative TACE on both disease-free survival and the pattern of recurrence after curative resection. From March 1998 to January 2005, a series of 273 patients who underwent curative resection for HCC were reviewed. Altogether, 120 patients underwent preoperative TACE, and 153 patients did not. We compared disease-free survival and the recurrence patterns between TACE and non-TACE groups, as well as between subgroups, stratified with regard to initial tumor size (≤3 cm, 3-5 cm, >5 cm) and pathologic tumor stage (stage I-II and stage III-IVa). We also compared disease-free survival and the pattern of recurrence among the three groups: complete necrosis, incomplete necrosis, non-TACE groups. Results: The 1-, 3-, and 5-year disease-free survival rates were 76.0%, 57.7%, and 51.3%, respectively, in the TACE group and 70.9%, 53.8%, and 46.8%, respectively, in the non-TACE group. No significant difference was observed in disease-free survival or the pattern of recurrence between the TACE and non-TACE groups. Further analysis of disease-free survival and the pattern of recurrence between subgroups according to initial tumor size and tumor stage showed no significant differences. Complete necrosis of tumor was recognized in only 33 patients of the TACE group (p = 0.001). Among the three complete necrosis, incomplete necrosis, and non-TACE groups, no significant difference was observed in disease-free survival or the pattern of recurrence. Conclusions: Preoperative TACE did not significantly improve the disease-free survival or the pattern of recurrence after curative resection of HCC. Even though this study is a retrospective analysis, preoperative TACE cannot be recommended as a routine procedure before hepatectomy for a resectable HCC.

AB - Background: Whether preoperative transarterial chemoembolization (TACE) has the therapeutic benefits in patients with resectable hepatocellular carcinoma (HCC) remains uncertain. Materials and methods: We retrospectively investigated the influence of preoperative TACE on both disease-free survival and the pattern of recurrence after curative resection. From March 1998 to January 2005, a series of 273 patients who underwent curative resection for HCC were reviewed. Altogether, 120 patients underwent preoperative TACE, and 153 patients did not. We compared disease-free survival and the recurrence patterns between TACE and non-TACE groups, as well as between subgroups, stratified with regard to initial tumor size (≤3 cm, 3-5 cm, >5 cm) and pathologic tumor stage (stage I-II and stage III-IVa). We also compared disease-free survival and the pattern of recurrence among the three groups: complete necrosis, incomplete necrosis, non-TACE groups. Results: The 1-, 3-, and 5-year disease-free survival rates were 76.0%, 57.7%, and 51.3%, respectively, in the TACE group and 70.9%, 53.8%, and 46.8%, respectively, in the non-TACE group. No significant difference was observed in disease-free survival or the pattern of recurrence between the TACE and non-TACE groups. Further analysis of disease-free survival and the pattern of recurrence between subgroups according to initial tumor size and tumor stage showed no significant differences. Complete necrosis of tumor was recognized in only 33 patients of the TACE group (p = 0.001). Among the three complete necrosis, incomplete necrosis, and non-TACE groups, no significant difference was observed in disease-free survival or the pattern of recurrence. Conclusions: Preoperative TACE did not significantly improve the disease-free survival or the pattern of recurrence after curative resection of HCC. Even though this study is a retrospective analysis, preoperative TACE cannot be recommended as a routine procedure before hepatectomy for a resectable HCC.

UR - http://www.scopus.com/inward/record.url?scp=36849081299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849081299&partnerID=8YFLogxK

U2 - 10.1007/s00268-007-9245-6

DO - 10.1007/s00268-007-9245-6

M3 - Article

VL - 31

SP - 2370

EP - 2377

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 12

ER -